Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Sep 21, 2023 (3 years ago)

lidocaine 2%

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of assurance of sterility:

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

lidocaine 2%, 100 mg/5 mL, (20 mg/mL), 5 mL Syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-6006-1

Affected NDC 71286-6006-01

Compare with the code on your package — it is the most precise check available.

Drug: Lidocaine

Recalling firm
Central Admixture Pharmacy Services Inc
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0004-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Lidocaine recalls

See all
Class II · Moderate risk

Lidocaine Ointment USP

Failed Content Uniformity Specifications. Out of Specification for Assay during analysis at the 24- month long term stability station, at (25¿C,60%RH).

Ongoing Wrong potency / content Sun Pharma /Taro D-0848-2026
Class III · Low risk

Lidolog Kit

Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan

Ongoing Labeling / mix-up Asclemed USA Inc. D-0713-2026

Other recalls by Central Admixture Pharmacy Services Inc

All 2023 recalls